Clinical Trial: Lanreotide as Treatment of Polycystic Livers
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers
Brief Summary: To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.
Detailed Summary:
Sponsor: Radboud University
Current Primary Outcome: Reduction of total liver volume as determined by CT scan [ Time Frame: 6 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Reduction of liver volume and individual cyst volume on CT scan. [ Time Frame: 6 months ]
- Change of kidney volume and individual cyst volume on CT scan [ Time Frame: 6 months ]
- Symptom evaluation by (validated) questionnaires [ Time Frame: 6 months ]
Original Secondary Outcome: Same as current
Information By: Radboud University
Dates:
Date Received: November 28, 2007
Date Started: October 2007
Date Completion:
Last Updated: February 16, 2009
Last Verified: February 2009
